A medical technology executive with more than 25 years of experience, Kevin Lawson is an expert in quality systems and regulatory affairs responsible for building numerous corporate quality management systems and regulatory clearance of hundreds of medical devices, in vitro diagnostic devices, and laboratory developed tests in the US and international markets.
Lawson managed regulatory affairs, commercial development and launch of novel products for international biotech companies leading to the founding of his company, KSL Diagnostics, in 2018, which delivers quality / regulatory consulting, CRO services and clinical diagnostics to international partners. KSL now employs >100 staff in its locations in the US, Canada and China. Lawson serves as President and CEO of KSL.
At Jacobs Institute, Lawson manages FDA submissions and supports GMP, GLP and ISO 13485 compliance.